Navigation Links
SGI Introduces the SGI BioCluster Life Sciences Workflow Solution
Date:12/11/2007

SGI Altix XE Cluster with eXludus Grid Optimizer Delivers 90 Percent

Acceleration of BLASTn and 70 Percent Acceleration of HMMER

SUNNYVALE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- With clusters the fastest growing segment of the computer market in biosciences according to the IDC industry analyst report "HPC Market and Research Overview: 2006 and Beyond", SGI (Nasdaq: SGIC) introduces the SGI(R) BioCluster, a powerful and accelerated workflow solution for pharmaceutical, life sciences and higher education researchers. The SGI BioCluster is an SGI(R) Altix(R) XE cluster system with PBS Pro cluster management tools and the eXludus Grid Optimizer(TM), a new multi-core capacity management technology that substantially boosts throughput in clusters and grids running workloads with tens, hundreds or thousands of concurrent users through its unique real-time job schedule optimization technology.

Two life sciences software applications have been benchmarked by eXludus on the SGI BioCluster thus far, using a 64-processor configuration. There was a 70 percent performance acceleration of HMMER and 90 percent acceleration on BLASTn, compared to a SGI Altix XE cluster using PBS Pro only.

"The high performance gains we achieved on in-house benchmarks are a result of the combination of our new Grid Optimizer, which is designed to increase the throughput efficiency of multi-core processors and prevent them from interfering with one another and the scalable architecture of the SGI Altix XE," said Benoit Marchand, founder and CEO of eXludus. "As we developed this technology we found that not only does performance increase, but performances of certain classes of applications accelerate tremendously, specifically bioinformati
'/>"/>

SOURCE SGI
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Delta Dental of Illinois Introduces Smile Smart For Your Health
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
5. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
6. Triveris Introduces Personal Health Record with Built-in Health Advisor
7. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
8. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
9. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
10. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
11. ThermoTx Introduces New Mobile Stimulation (TENS) Product Line for On the Go Therapy and Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 57745 1New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 57745 2New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 57745 3New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 57745 4Aurora Capital to Acquire Porex Corporation Leader in Porous Plastic Materials Science 57741 1Aurora Capital to Acquire Porex Corporation Leader in Porous Plastic Materials Science 57741 2Aurora Capital to Acquire Porex Corporation Leader in Porous Plastic Materials Science 57741 3Measuring Pain from the Patients Point of View 57738 1Measuring Pain from the Patients Point of View 57738 2